Feb 25, 2019 8:05am EST Prominent Cardiovascular Expert, James J. Ferguson, M.D., FACC, FAHA Joins Matinas BioPharma as Chief Medical Officer
Jan 10, 2019 8:00am EST Matinas BioPharma Announces a Research Evaluation with Top Global Pharma Company Based on Its Proprietary Drug Delivery Platform
Jan 03, 2019 8:20am EST Matinas BioPharma Appoints Keith A. Kucinski, CPA, MBA as Chief Financial Officer
Dec 19, 2018 8:35am EST Matinas BioPharma Appoints Harold E. Bays, M.D. to its Cardiovascular Health Scientific Advisory Board
Dec 06, 2018 9:00am EST Matinas BioPharma Assembles World Class Scientific Advisory Board to Guide Clinical Development Strategy of Potential Best-in-Class Prescription-Only Omega-3, MAT9001
Nov 12, 2018 7:00am EST Matinas BioPharma Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Oct 18, 2018 8:00am EDT Matinas BioPharma Announces Issuance of Key U.S. Patent for Prescription-Only Next Generation Omega-3 MAT9001 Providing Protection Through 2033
Oct 16, 2018 8:00am EDT Matinas BioPharma to Present at the 8th Annual Partnership Opportunities in Drug Delivery Conference
Oct 15, 2018 8:01am EDT Matinas BioPharma Appoints Global Pharmaceutical Drug Development Industry Leader Theresa Matkovits, Ph.D., Chief Development Officer; Further Expands Manufacturing and Clinical Development Team
